TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3000412

Group type: EXPERIMENTAL
Intervention: RT plus ACNU (100 mg/m2 on day 1 and 42)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: RT plus ACNU and tegafur (400 mg/m2, daily for 8 weeks)
Number of subjects: 105

Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: RT plus ACNU
Number of subjects: 105
Study: 29193478

Group type: EXPERIMENTAL
Intervention: Carvacrol capsule (1.2 mg/kg/day) for 2 months
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 27955648

Group type: EXPERIMENTAL
Intervention: Statewide health promotion intervention in primary schools
Number of subjects: 1943

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1943
Study: 23744488

Group type: EXPERIMENTAL
Intervention: Pleuran (β-glucan from Pleurotus ostreatus)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22974220

Group type: EXPERIMENTAL
Intervention: Tourniquet
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-Tourniquet
Number of subjects: 50
Study: 20451896

Group type: EXPERIMENTAL
Intervention: Ahmed valve implant (model FP7; 184 mm² surface area)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Molteno single-plate implant (134 mm² surface area)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 92
Study: 18630765

Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.25% 10 mL epidurally
Number of subjects: 40

Group type: COMPARATOR
Intervention: piritramide 0.08 mg kg(‐1) i.v.
Number of subjects: 40
Study: 15839958

Group type: EXPERIMENTAL
Intervention: Combination of carboplatin and paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraperitoneal therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maintenance/consolidation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addition of a third non-cross-resistant drug to carboplatin and paclitaxel
Number of subjects: 0
Study: 11886010

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) treatment
Number of subjects: 3825
Study: 9987087

Group type: COMPARATOR
Intervention: 60 mg FU plus a sham infusion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 60 mg FU plus 200 ml of a 20% solution of HA
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sham infusion plus 200 ml of a 20% solution of HA
Number of subjects: 9
Study: 7561818

Group type: EXPERIMENTAL
Intervention: Behavioral skills training
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Intensive case management
Number of subjects: 132

Group type: COMPARATOR
Intervention: Twelve Step recovery
Number of subjects: 132
Study: 2075482

Group type: EXPERIMENTAL
Intervention: Fansimef (MSP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lariam (MEF)
Number of subjects: 0
Study: 7027893

Group type: EXPERIMENTAL
Intervention: Fixed combination of metoprolol 100 mg and hydrochlorothiazide 12.5 mg (group A) b.i.d for 12 weeks
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Fixed combination of metoprolol 100 mg and hydrochlorothiazide 25 mg (group B) b.i.d for 12 weeks
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Low dose combination of hydrochlorothiazide with metoprolol
Number of subjects: 55
Study: 30381901

Group type: EXPERIMENTAL
Intervention: High protein diet (approximately 25 g of protein from 125 g per week of sardine, advised to restrict carbohydrate intake)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Isocaloric diet (1,800 kcal) with nutritional counselling to follow national nutrition guidelines (15% protein, 60% carbohydrates, and 25% lipids)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 94
Study: 27853891

Group type: EXPERIMENTAL
Intervention: Ginsenoside Rb1 (500 mg daily oral administration, n = 103)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo (n = 94)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Ginsenoside Rb1
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 25646809

Group type: EXPERIMENTAL
Intervention: Sleep hygiene practices and standardised behavioural strategies delivered by trained psychologists or trainee paediatricians during two fortnightly consultations and a follow‐up telephone call
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Sleep hygiene practices and standardised behavioural strategies
Number of subjects: 244
Study: 24422876

Group type: EXPERIMENTAL
Intervention: Exercise-based physiotherapy intervention (B)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Manual therapy-based physiotherapy intervention (C)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Usual care (control - A)
Number of subjects: 600
Study: 20948461

Group type: EXPERIMENTAL
Intervention: Posterior multilevel vertebral osteotomy (PMVO)
Number of subjects: 13
Study: 19263013

Group type: EXPERIMENTAL
Intervention: 2005 CPR guidelines
Number of subjects: 49

Group type: COMPARATOR
Intervention: 2000 CPR guidelines
Number of subjects: 49
Study: 17075367

Group type: EXPERIMENTAL
Intervention: 7.2% saline in 6% hydroxyethyl starch (HSS)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 22
Study: 14702492

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (aimed at providing 1800 mg of Ca/day)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo (indistinguishable from calcium-containing liquid)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 11720117

Group type: EXPERIMENTAL
Intervention: Barthel Index (BI)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Rivermead Mobility Index (RMI)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nottingham Extended Activities of Daily Living Scale (NEADL)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Frenchay Activities Index (FAI)
Number of subjects: 22
Study: 9211770

Group type: EXPERIMENTAL
Intervention: Iodixanol (Visipaque 270 mg I/ml)
Number of subjects: 2452

Group type: COMPARATOR
Intervention: Iopromide (Ultravist 300 mg I/ml)
Number of subjects: 2452
Study: 7962398

Group type: EXPERIMENTAL
Intervention: Men whose partners experience unexplained recurrent spontaneous abortion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Men whose partners have normal reproductive histories
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Men whose partners have cellular immunity to sperm antigens
Number of subjects: 0
Study: 3610514

Group type: EXPERIMENTAL
Intervention: 0.1% benzydamine solution
Number of subjects: 100

Group type: COMPARATOR
Intervention: povidone-iodine vaginal suppositories
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0.2% aluminium acetate solution
Number of subjects: 100
Study: 31411950

Group type: EXPERIMENTAL
Intervention: Gefitinib plus Pemetrexed and Carboplatin (Gef+C)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Gefitinib (Gef)
Number of subjects: 350
Study: 29042177

Group type: EXPERIMENTAL
Intervention: Ivacaftor
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Any change in antibiotic exposure
Number of subjects: 20
Study: 27827949

Group type: EXPERIMENTAL
Intervention: Hypoxia + carbohydrate supplementation (6% carbohydrate solution, maltodextrin)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 7

Group type: COMPARATOR
Intervention: Hypoxia
Number of subjects: 7
Study: 25511050

Group type: EXPERIMENTAL
Intervention: Oral squamous cell carcinoma (OSCC) patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (normal healthy volunteers)
Number of subjects: 30
Study: 22283392

Group type: EXPERIMENTAL
Intervention: Screened population (n = 1705)
Number of subjects: 4936

Group type: COMPARATOR
Intervention: Unscreened population (n = 1705)
Number of subjects: 4936

Group type: EXPERIMENTAL
Intervention: Screened population
Number of subjects: 4936

Group type: COMPARATOR
Intervention: Unscreened population
Number of subjects: 4936
Study: 21524564

Group type: EXPERIMENTAL
Intervention: CFVR measurement during adenosine-induced hyperemia in the left anterior descending artery, left circumflex artery, and posterior descending artery.
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Combined echocardiographic criteria (pCFVR <2.0 or retrograde coronary artery flow).
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: CFVR measurement in the mid to distal left anterior descending artery.
Number of subjects: 108
Study: 18023439

Group type: EXPERIMENTAL
Intervention: Triptorelin (0.2 mg SC) in addition to hCG (5,000 U) 34 hours before oocyte aspiration
Number of subjects: 221

Group type: COMPARATOR
Intervention: hCG (5,000 U) 34 hours before oocyte aspiration (Control group)
Number of subjects: 221
Study: 17056947

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 110

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 110
Study: 14724722

Group type: EXPERIMENTAL
Intervention: Asthma education (four 1-hour sessions of group education)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (no instruction)
Number of subjects: 85
Study: 11034651

Group type: EXPERIMENTAL
Intervention: BAK/C fusion cage(s)
Number of subjects: 344

Group type: COMPARATOR
Intervention: ACDF (anterior cervical discectomy with uninstrumented bone‐only fusion)
Number of subjects: 344

Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: BAK/C
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Both BAK/C and ACDF
Number of subjects: 344
Study: 8681017

Group type: EXPERIMENTAL
Intervention: Myocardial perfusion imaging (thallium imaging)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radionuclide studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-invasive testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prognostic variables (thallium imaging)
Number of subjects: 0
Study: 1433581

Group type: EXPERIMENTAL
Intervention: Medical treatment with prophylactic antibacterials
Number of subjects: 306

Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 306
Study: 4080137

Group type: EXPERIMENTAL
Intervention: High anxiety treatment group
Number of subjects: 39

Group type: COMPARATOR
Intervention: Low anxiety treatment group
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Visuospatial questioning
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Anxiety content of questions
Number of subjects: 39
Study: 31531962

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 0

Group type: COMPARATOR
Intervention: Duloxetine
Number of subjects: 0
Study: 29458278

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secukinumab 75 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg and 75 mg
Number of subjects: 0
Study: 26984932

Group type: EXPERIMENTAL
Intervention: Orbital atherectomy
Number of subjects: 443
Study: 24998572

Group type: EXPERIMENTAL
Intervention: KHRA-based counseling
Number of subjects: 332

Group type: COMPARATOR
Intervention: Conventional counseling
Number of subjects: 332
Study: 23013162

Group type: EXPERIMENTAL
Intervention: One week multidisciplinary inpatient self-management programme (SMP)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 150
Study: 20672296

Group type: EXPERIMENTAL
Intervention: 75 mg aztreonam for inhalation solution (AZLI) administered two (BID) or three times daily (TID) for up to nine courses (28 days on/28 days off)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: 75 mg aztreonam for inhalation solution (AZLI) administered two (BID) or three times daily (TID)
Number of subjects: 274
Study: 17133181

Group type: EXPERIMENTAL
Intervention: DAA+
Number of subjects: 36

Group type: COMPARATOR
Intervention: DAA-
Number of subjects: 36
Study: 14767021

Group type: EXPERIMENTAL
Intervention: Doppler-derived S/D ratio >1.33
Number of subjects: 118
Study: 11518836

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring using the Omron HEM‐702 monitor
Number of subjects: 40

Group type: COMPARATOR
Intervention: Clinic blood pressure monitoring by project nurse
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring
Number of subjects: 40

Group type: COMPARATOR
Intervention: Home blood pressure monitoring and clinic blood pressure monitoring
Number of subjects: 40
Study: 9890718

Group type: EXPERIMENTAL
Intervention: D-dimer concentration on the third postoperative day in patients with DVT (n = 47)
Number of subjects: 118

Group type: COMPARATOR
Intervention: D-dimer concentration on the third postoperative day in patients without DVT (n = 64)
Number of subjects: 118

Group type: COMPARATOR
Intervention: D-dimer concentrations pre-operatively and at the time of phlebography
Number of subjects: 118
Study: 8032546

Group type: EXPERIMENTAL
Intervention: 0.9 MIU/m2 IL-2 administered subcutaneously once weekly (4 doses, stratum I)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 0.9 MIU/m2 IL-2 administered subcutaneously three times a week every other day (9 doses, stratum II)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 0.9 MIU/m2 IL-2 administered subcutaneously five times a week every other week (10 doses, stratum III)
Number of subjects: 28
Study: 2583878

Group type: EXPERIMENTAL
Intervention: Inderal
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ciplar
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Corbeta
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Propal
Number of subjects: 6
Study: 1091171

Group type: EXPERIMENTAL
Intervention: Oral colistin sulfate (non-absorbable broad-spectrum antimicrobial)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31150087

Group type: EXPERIMENTAL
Intervention: FLEX intervention (behavioral counseling strategy integrating motivational interviewing and problem-solving skills training)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: FLEX intervention
Number of subjects: 258

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 258
Study: 29184759

Group type: EXPERIMENTAL
Intervention: Hypothenar fat pad flap (HTFPF)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional open carpal tunnel release (COR)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both HTFPF and COR
Number of subjects: 37
Study: 26142837

Group type: EXPERIMENTAL
Intervention: Implementation intentions
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 30
Study: 23356250

Group type: EXPERIMENTAL
Intervention: Lime juice treatment
Number of subjects: 113
Study: 22020019

Group type: EXPERIMENTAL
Intervention: Wok size 36 cm with handle angle -20°
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Wok size 39 cm
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Wok size 42 cm
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Handle angle 25°
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Handle angle 10°
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Handle angle -5°
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Handle angle -20°
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Handle angle -35°
Number of subjects: 12
Study: 19657201

Group type: EXPERIMENTAL
Intervention: Aconitum napellus C30
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 16732082

Group type: EXPERIMENTAL
Intervention: No. 2 Macintosh curved blade (MCB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No. 3 Macintosh curved blade (MCB)
Number of subjects: 100
Study: 15618379

Group type: EXPERIMENTAL
Intervention: Radiography and short MR imaging examination
Number of subjects: 87

Group type: COMPARATOR
Intervention: Radiography
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Negative MR imaging results
Number of subjects: 87
Study: 11841454

Group type: EXPERIMENTAL
Intervention: 8 microg/kg/d rhG-CSF
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 16 microg/kg/d rhG-CSF
Number of subjects: 50
Study: 10191336

Group type: COMPARATOR
Intervention: Grip force adjustments in older adults (60 years and older) when friction of gripped surfaces was varied randomly.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Grip force adjustments in older adults (60 years and older) on slippery surfaces during friction variation experiments.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Grip force adjustments in older adults (60 years and older) compared to young subjects.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anticipatory control of fingertip forces using memory of object weight in older adults.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fingertip force modulation in old and young adults.
Number of subjects: 0
Study: 7758326

Group type: EXPERIMENTAL
Intervention: 5% sodium lauryl sulphate at 4 degrees C
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 5% sodium lauryl sulphate at 20 degrees C
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 5% sodium lauryl sulphate at 40 degrees C
Number of subjects: 10

Group type: COMPARATOR
Intervention: Untreated control site
Number of subjects: 10
Study: 2189276

Group type: EXPERIMENTAL
Intervention: Ankerplast Spray
Number of subjects: 597

Group type: COMPARATOR
Intervention: Control group (no Ankerplast Spray)
Number of subjects: 597
Study: 582395

Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Anger-provoking situation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neutral control situation
Number of subjects: 60
Study: 31969796

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: HCR
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: MV-PCI
Number of subjects: 155
Study: 30549366

Group type: EXPERIMENTAL
Intervention: Transtheoretical model (TTM)-based intervention
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92
Study: 28973414

Group type: EXPERIMENTAL
Intervention: 0.2% polidocanol diluted in 70% hypertonic glucose (HG)
Number of subjects: 93

Group type: COMPARATOR
Intervention: 75% hypertonic glucose (HG) alone
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 93
Study: 26254820

Group type: EXPERIMENTAL
Intervention: Microvascular couplers used for anastomosis
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Microvascular couplers used for venous anastomosis
Number of subjects: 64
Study: 24078483

Group type: EXPERIMENTAL
Intervention: Active group received LLLT using a 'TOPHAT655' unit with 21 lasers (5 mW, 655 ± 5 nm) and 30 LEDs (655 ± 20 nm), treated at home every other day for 16 weeks (60 treatments).
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo group received a unit with incandescent red lights, treated at home every other day for 16 weeks (60 treatments).
Number of subjects: 44
Study: 20683712

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (800 IU/day)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 IU/3 months)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Advised sunlight exposure
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: All groups (including sunlight exposure)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Physical performance and functional limitations
Number of subjects: 232
Study: 19664320

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural group therapy (CBGT)
Number of subjects: 27
Study: 17684199

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.5 mg/kg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 15305399

Group type: EXPERIMENTAL
Intervention: Concomitant administration of epirubicin (90 mg/m2) and paclitaxel (200 mg/m2) for 8 cycles
Number of subjects: 202

Group type: COMPARATOR
Intervention: Sequential administration of epirubicin (120 mg/m2 for 4 cycles) followed by paclitaxel (250 mg/m2 over 3 hours for 4 cycles)
Number of subjects: 202
Study: 11453871

Group type: EXPERIMENTAL
Intervention: Vitamin E-modified membrane (E)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Nonmodified cellulose membrane (O)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Vitamin E-modified membrane (E) with Vitamin C infusion (C)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Nonmodified cellulose membrane (O) with Vitamin C infusion (C)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Vitamin E-modified membrane (E) in long-term study with Vitamin C (C)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Vitamin E-modified membrane (E) in long-term study without Vitamin C (C)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Switch to Nonmodified cellulose membrane (O)
Number of subjects: 44
Study: 9749148

Group type: EXPERIMENTAL
Intervention: MAPA‐PC software for comparing ABPM
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: MAPA‐PC software
Number of subjects: 79
Study: 7804393

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 16
Study: 2454128

Group type: EXPERIMENTAL
Intervention: 6% dextran added to lignocaine solution containing adrenaline
Number of subjects: 27

Group type: COMPARATOR
Intervention: Lignocaine solution containing adrenaline without dextran
Number of subjects: 27
Study: 30764649

Group type: EXPERIMENTAL
Intervention: Conventional 10-Hz rTMS
Number of subjects: 388

Group type: COMPARATOR
Intervention: Intermittent theta burst stimulation (iTBS) rTMS
Number of subjects: 388
Study: 29074098

Group type: EXPERIMENTAL
Intervention: Lorlatinib (100 mg once daily)
Number of subjects: 54
Study: 25212278

Group type: EXPERIMENTAL
Intervention: IMN (0.6 L/d)
Number of subjects: 120

Group type: COMPARATOR
Intervention: CON (isocaloric control)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: IMN
Number of subjects: 120

Group type: COMPARATOR
Intervention: CON
Number of subjects: 120
Study: 24284608

Group type: EXPERIMENTAL
Intervention: Complementary foods from 4 months (CF)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Exclusive breastfeeding to 6 months (EBF)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Both groups evaluated with Brigance Screens‐II at 30‐35 months
Number of subjects: 119
Study: 22120443

Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive-Behavior Therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait List Controls (WL)
Number of subjects: 0